*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.
Johnson & Johnson's upcoming earnings report on October 14th is set against the backdrop of its robust market capitalization of over $453 billion, underscoring its significant presence in the healthcare sector. Analysts are closely watching the company's performance, with an EPS estimate of $2.75 and revenue expected to reach $23.74 billion. The whisper number, slightly higher at $2.78, suggests that investor sentiment is cautiously optimistic, anticipating that Johnson & Johnson may slightly outperform official expectations. This anticipation is likely fueled by the company's consistent track record of strategic innovation and its ability to navigate market challenges effectively. As Johnson & Johnson continues to leverage its diverse portfolio, the upcoming earnings release will be pivotal in assessing its ongoing growth trajectory and market resilience.
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Website: https://www.jnj.com
Average Sentiment Score:
Overall Sentiment: